SCHEMBL30855321

SCHEMBL30855321

CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCC(c3noc4cc(F)ccc34)CC2)CC1

nearest known ligand 0.80

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 20/20 0.80
DRD3 P35462 20/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL607399 1.00 HTR2A (0.80) HTR2ADRD3
SCHEMBL16004607 0.93 HTR2A (0.80) HTR2ADRD3
SCHEMBL607475 0.93 HTR2A (0.80) HTR2ADRD3
SCHEMBL4208408 0.90 HTR2A (0.80) HTR2ADRD3
SCHEMBL606642 0.90 HTR2A (0.80) HTR2ADRD3
SCHEMBL10164238 0.89 HTR2A (1.00) HTR2ADRD3
SCHEMBL10164205 0.88 HTR2A (0.62) HTR2ADRD3
SCHEMBL21026223 0.86 HTR2A (0.82) HTR2ADRD3
SCHEMBL607356 0.86 HTR2A (1.00) HTR2ADRD3
SCHEMBL15859546 0.85 HTR2A (0.81) HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594294-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2025-08-06 EP disclosed
WO-2024072930-A1 DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-04-04 WO disclosed